Sensus Healthcare, Inc. (SRTS) - 10-K Summary for Fiscal Year Ended December 31, 2025
Business Context and Reporting Period
This Annual Report on Form 10-K covers the fiscal year ended December 31, 2025. Sensus Healthcare, Inc. is a medical device company specializing in superficial radiation therapy (SRT) for non-melanoma skin cancer (NMSC) and keloid scar prevention. The Company operates as a single segment from its headquarters in Boca Raton, Florida, with manufacturing outsourced to third parties. As of year-end, the Company had 60 employees and 955 installed units globally, primarily in the United States.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenues | $27,482 | $41,807 |
| Cost of Sales | $15,615 | $17,376 |
| Gross Profit | $11,867 | $24,431 |
| Gross Margin | 43.3% | 58.4% |
| Operating Expenses | $22,174 | $16,341 |
| Net (Loss) Income | $(7,719) | $6,647 |
| Cash and Cash Equivalents | $22,083 | $22,056 |
| Debt (Revolving Credit Facility) | $0 | $0 |
Additional Metrics:
- Units Sold: 70 units in 2025 (down from 115 in 2024).
- Research & Development (R&D): $7.8 million in 2025, driven by lobbying costs and product development.
- Inventory: Increased to $14.6 million (up 44% from 2024) in anticipation of future sales.
- Accounts Receivable: Decreased to $6.0 million (down 70% from 2024) due to lower sales volume.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 34% to $27.5 million, primarily due to a significant reduction in sales to the Company's largest U.S. customer (who accounted for 52% of 2025 revenue vs. 73% in 2024) and lower unit sales.
- Profitability Reversal: The Company reported a net loss of $7.7 million in 2025, reversing the profitability achieved in 2021 through 2024. This was driven by lower gross profit and a sharp increase in operating expenses.
- Expense Increases:
- R&D Expenses: Increased 86% to $7.8 million, largely due to lobbying costs to secure new reimbursement codes and development of next-generation systems.
- Selling & Marketing: Increased 30% to $6.5 million due to higher headcount and tradeshow costs.
- Customer Concentration: While the largest customer's share of revenue decreased from 73% to 52%, the Company remains highly dependent on this single entity and the U.S. market (92% of total revenue).
Guidance, Outlook, and Risks
Outlook and Management Commentary:
- Reimbursement Changes: New CMS CPT codes for SRT took effect on January 1, 2026, with increased reimbursement rates. Management expects this to drive demand in 2026.
- Strategic Initiatives: The Company launched "Sensus Healthcare Financial Services" (financing program) and "Sensus Link" (cloud-based software) in February 2026 to support sales and workflow efficiency.
- 2026 Expectations: Management anticipates R&D expenses will be substantially lower in 2026. However, uncertainties remain regarding demand from the largest customer, inflation, and the adoption of higher-priced devices.
Risks and Contingencies:
- Credit Facility Default: As of December 31, 2025, the Company was in default of its revolving credit facility with Comerica Bank due to failing the minimum profitability covenant ($1.0 million trailing 12-month basis). No borrowings were outstanding, but the default status poses a liquidity risk. The lender (Comerica) was acquired by Fifth Third in February 2026, and the impact is being evaluated.
- Customer Concentration: Loss of or reduced orders from the single largest customer could materially harm operations.
- Regulatory & Legal: The Company is subject to an ongoing Department of Justice investigation regarding billing practices by a physician using its devices. No liability has been recorded as the outcome is uncertain.
- Supply Chain: Reliance on a single preferred supplier for x-ray tubes and major components.
Key Facts for Investor Verification
- Credit Facility Status: Verify the resolution of the profitability covenant default with the new lender (Fifth Third) and the availability of the $15 million credit line.
- Largest Customer Relationship: Assess the stability of the relationship with the customer representing 52% of revenue and the impact of their purchasing patterns on future guidance.
- Reimbursement Impact: Monitor the actual uptake of the new 2026 CMS CPT codes and whether the anticipated increase in demand materializes.
- Inventory Levels: Review the $14.6 million inventory balance to ensure it aligns with realistic sales forecasts given the recent revenue decline.
- DOJ Investigation: Track any developments in the Department of Justice investigation regarding Medicare billing codes.